



حدسته

A ...

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: MacDonald et al.

Serial No.: 10/667,096 Art Unit: Unassigned

Filed : September 18, 2003 Examiner: Unassigned

For : METHODS OF INCREASING PLATELET AND HEMATOPOIETIC

STEM CELL PRODUCTION

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

January 23, 2004 (Date of Deposit)

Laura A. Donnelly (Name of applicant, assignee, or Registered Representative)

James a Donnely

January 23, 2004 (Date of Signature)

MAIL STOP DD Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §\$1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

$oxed{\boxtimes}$ In accordance with $\$1.97(b)$, since this Information
Disclosure Statement is being filed either within three months
of the filing date of the above-identified national application
(other than a continued prosecution application under
§1.53(d)), within three months of the date of entry into the
national stage of the above identified application as set forth
in §1.491, or before the mailing date of a first Office Action
on the merits of the above-identified application, or before
the mailing date of a first Office Action after the filing of a
request for continued examination under \$1.114, no additional
fee is required.
☐ In accordance with §1.129(a), this Information
Disclosure Statement is being filed in connection with \square the
first or second After Final Submission, therefore:
<pre>Statement in Accordance with §1.97(e)</pre>
(attached); or
☐ Please charge Deposit Account No. 10-
0750/ / the fee of $$180.00$ as set forth
in \$1.17(p).
The accordance with \$1,07(a) this Information
☐ In accordance with \$1.97(c), this Information
Disclosure Statement is being filed after the period set forth
in §1.97(b) above but before the mailing date of either a Final
Action under §1.113 or a Notice of Allowance under §1.311, or
an action that otherwise closes prosecution and that it is
accompanied by one of:
<pre>Statement in Accordance with §1.97(e)</pre>
(attached); or

	Please charge Deposit Account No. 10-
	0750/ / the fee of \$180.00 as set forth
	in §1.17(p).
☐ In ac	ccordance with §1.97(d), this Information
Disclosure Stat	ement is being filed after the mailing date of
either a Final	Action under §1.113 or a Notice of Allowance
under §1.311 b	out before the payment of the Issue Fee.
Applicant(s) he	reby petition(s) for consideration of this
Information Dis	closure Statement. Included are: Statement in
Accordance with	§1.97(e) as set forth below and the fee of
\$180.00 as set	forth in §1.17(p).
_	
	es of each of the references listed on the
attached Form F	TO-1449 are enclosed herewith.
☐ Copi∈	es of references listed on the attached Form PTO-
1449 are enclos	sed herewith EXCEPT THAT:
	In view of the voluminous nature of references
	[list as appropriate], and the likelihood that
	these references are available to the Examiner,
	copies are not enclosed herewith.
	If any of the foregoing publications are not
	available to the Examiner, Applicant will
	endeavor to supply copies at the Examiner's
	request.
•	
⊠ Copi∈	es of only foreign patent documents and non-
patent literatu	are are enclosed in accordance with 37 CFR 1.98
(a)(2). (The U	J.S. patents and each U.S. patent application
publication lis	sted on the attached Form PTO-1449 are not

enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the

national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i).

There are no listed references which are not in the 冈 English language. The relevance of those listed references which are not in the English language is as follows: Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D. Attached are the following non-published pending patent applications which may be deemed relevant, which are

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/PRD-2110-USANP/LAD. This form is submitted in triplicate.

listed on the attached Submission Under MPEP 609 D.

Respectfully submitted,

flert E. " mees Laura A. Donnelly

Reg. No. 38,435

Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-1729 DATED: January 23, 2004





PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
on a collection of information unless it discretes a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

a constructi of anothernor mices it dishala i	TARA CHILD CONTECT HUMBON.
Application Number	10/667,096
Filing Date	September 18, 2003
First Named Inventor	MacDonald et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	PRD-2110-USANP

	Cite No.1	U.S. Patent Document			D. A. of D. Librarian	Pages, Columns, Lines,		
Examiner Initials		into 1		Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	where relevant passages or relevant figures appear
			5,869,451	A1	Glaxo Group Limited	02/09/1999		
	ļ							
	<u> </u>							
	<u> </u>							
	ļ							

	Cite	Foreign Patent Docum		ment	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials		Office ³	Number ⁴	KindCode ⁵	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	T⁵
								Ь.
				A1		-		<u> </u>
							,	
		ļ						
	-	ļ						
	_					 		
								+-
								<u> </u>

Examiner	Date
Signature	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwo.
Substitute for form 1449A/PTO

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0551-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to a collection of information unless it displays a valid OMP acceptable.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

0	o a collection of information unless it displays a valid OMB control number.				
	Application Number	10/667,096			
	Filing Date	September 18, 2003			
	First Named Inventor	MacDonald et al.			
	Group Art Unit	Unassigned			
	Examiner Name	Unassigned			
	Attorney Docket Number	PRD-2110-USANP			
		1			

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Kaushansky et al., "Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoletin", Nature, Vol. 369, pp. 568-571 (1994)	
		Solar et al., "Role of c-mpl in Early Hematopoiesis", Blood, Vol. 92, pp. 4-10 (1998)	
		Ku et al., "Thrombopoietin, the Ligand for the Mpl Receptor, Synergizes With Steel Factor and Other Early Acting Cytokines in Supporting Proliferation of Primitive Hematopoietic Progenitors of Mice", Blood, Vol. 87, pp. 4544-4551 (1996)	
		Sitnicka et al., "The Effect of Thrombopoietin on the Proliferation and Differentiation of Murine Hematopoietic Stem Cells", Blood, Vol. 87, pp. 4998-5005 (1996)	
		Kimura et al., "Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin", Proc. Natl. Acad. Sci. U.S.A., Vol. 95, pp. 1195-1200 (1998)	
		Ballmaier et al., "c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia", Blood, Vol. 97, pp. 139-146 (2001)	
		Fox et al., "Thrombopoietin expands hematopoietic stem cells after transplantation", J. Clin. Invest., Vol. 110, pp. 389-394 (2002)	
	<u> </u>		
···	<u> </u>		
	 		
		·	
	 		

Examiner	·	Date	
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.



Serial No. 10 667, 096 Docket No. PW-7110-W.A Malication of: MW DWDD LAD Mailed: TAN WAY 33, 2004 Entitled: MY Thodo of Increasing Plain of the Architecture of the Steph Call Continued to Steph Continued to Steph Call Continued to Steph Call Continued to Steph Call Continued to Steph Call Continued to Steph Continued t	 ☐ MPEP 609/ ☐ Notice of Appeal ☐ Brief ☐ Priority Document ☐ Status Inquiry ☐ Sequence Listings/Diskette ☐ Biological Deposit Declaration ☐ Other
Serial No. 10 667, 096 Application of: MALDWALL LAL Mailed: TAL Entitled: MAThods of Incredictory to plain the following has been received in the U.S. Patent office	☐ Oath or Declaration ☐ Assignment ☐ Charge to Deposit Account 10-0750 ☐ Amendment ☐ Extension of Time ☐ Issue Fee Transmittal ☐ PCT Filing ☐ Drawings sheets